Pre-emptive treatment with DNMT3A-R882H neoantigen-directed immunotherapy may be particularly attractive to prevent disease recurrence in patients with CHIP/CCUS who are in remission after treatment for AML. Here, DNMT3A is linked to acute myeloid leukemia.